Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by CNB Bank

CNB Bank raised its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 5.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,434 shares of the company’s stock after buying an additional 651 shares during the period. Johnson & Johnson makes up about 1.1% of CNB Bank’s investment portfolio, making the stock its 20th largest holding. CNB Bank’s holdings in Johnson & Johnson were worth $2,207,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after purchasing an additional 3,358,478 shares in the last quarter. GQG Partners LLC grew its position in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares in the last quarter. Swiss National Bank grew its position in Johnson & Johnson by 14.0% during the 1st quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock worth $2,020,868,000 after purchasing an additional 1,396,500 shares in the last quarter. Finally, Bridgewater Associates LP grew its position in Johnson & Johnson by 40.3% during the 1st quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock worth $770,065,000 after purchasing an additional 1,247,260 shares in the last quarter. Institutional investors own 68.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on JNJ. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 19th. Atlantic Securities lowered their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Raymond James lowered their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Finally, Citigroup lowered their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Trading Up 0.5 %

Shares of NYSE:JNJ opened at $175.97 on Tuesday. The stock has a market capitalization of $460.07 billion, a PE ratio of 24.51, a P/E/G ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm has a fifty day moving average price of $168.04 and a 200 day moving average price of $171.28. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.60 earnings per share. Analysts expect that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is 62.95%.

Johnson & Johnson declared that its Board of Directors has approved a share buyback plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders sold a total of 135,723 shares of company stock valued at $23,192,574 in the last quarter. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.